Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0SEAFV
ADC Name	PYX-201
Synonyms	PYX201; PYX 201 Click to Show/Hide
Organization	Pfizer Inc.; Pyxis Oncology, Inc.
Drug Status	Phase 1
Indication	In total 1 Indication(s) Solid tumors [ICD11:2A00-2A0Z\|2B50-2F9Z] Phase 1
Drug-to-Antibody Ratio	4
Structure
	3D MOL	2D MOL
Antibody Name	Undisclosed
Antigen Name	Fibronectin (FN1)		Antigen Info
Payload Name	Auristatin 0101		Payload Info
Therapeutic Target	Microtubule (MT)		Target Info
Linker Name	Mc-Val-Cit-PABC		Linker Info
Conjugate Type	Random conjugation through reduced inter-chain cysteines.
Combination Type	Pelidotin

General Information of The Activity Data Related to This ADC

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	NCT Number	Clinical Status	Clinical Trial Description
Undisclosed	NCT05720117	Phase 1	A first-in-human, open-label, multicenter, phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PYX-201 in participants with advanced solid tumors. Click to Show/Hide

Full List of Activity Data of This Antibody-drug Conjugate

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
*Related Clinical Trial*
NCT Number	NCT05720117	Clinical Status	Phase 1
Clinical Description	A first-in-human, open-label, multicenter, phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PYX-201 in participants with advanced solid tumors.

References

Ref 1	A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Participants With Advanced Solid Tumors, NCT05720117